CD274 and neoplasm: Finally, the phase 3 the EMPOWER-Cervical 1 trial compared the efficacy of cemiplimab to a regimen of investigator’s choice chemotherapy (topotecan or irinotecan) in patients with recurrent or metastatic cervical cancer refractory to first-line platinum-based chemotherapy, regardless of their level of tumor PD-L1 expression [9,46].